Peptides Targeting Alpha7 Receptor for Neurodegenerative Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders like Alzheimer's disease, particularly those targeting the α7 nicotinic acetylcholine receptor, face limitations due to non-specific effects, low receptor affinity, and challenges in crossing the blood-brain barrier, leading to inadequate efficacy and side effects.
Innovation Solution
Design and synthesis of novel peptides and peptidomimetics with high affinity for the α7 nicotinic-receptor, specifically blocking the toxic effects of endogenous peptides T30 and beta-amyloid production, and potentially overcoming blood-brain barrier permeability issues through optimized chemical functionalities and delivery methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments targeting the α7 nicotinic acetylcholine receptor are used, then some therapeutic effect is achieved, but non-specific effects and low receptor affinity lead to inadequate efficacy and side effects
Solution Approach 1:
The patent applies local quality by designing peptides with specific amino acid sequences that target particular regions or conformations of the α7 nicotinic acetylcholine receptor. This localized targeting approach enhances binding affinity and specificity to the receptor's active site, thereby improving therapeutic efficacy while minimizing non-specific interactions that cause side effects.
Solution Approach 2:
The patent employs parameter changes by systematically modifying peptide sequences, molecular weight, hydrophobicity, and other physicochemical properties to optimize receptor binding. These parameter optimizations enable the peptides to achieve higher affinity and selectivity for the α7 receptor, resolving the contradiction between efficacy and side effects through precise molecular design.
2Reliability
If current treatments are administered, then some therapeutic effect is achieved, but low receptor affinity results in inadequate efficacy
Solution Approach 1:
The patent systematically optimizes peptide parameters including amino acid composition, sequence length, and structural conformation to maximize receptor binding affinity. By adjusting these parameters, the invention achieves high-affinity binding to the α7 nicotinic acetylcholine receptor, directly addressing the inadequacy of current treatments with low receptor affinity.
Solution Approach 2:
The patent utilizes composite peptide structures that combine multiple functional motifs within a single molecule. These composite designs include affinity-enhancing regions, stability-conferring elements, and receptor-binding domains, creating peptides with superior binding characteristics compared to simple linear sequences.
3Reliability
If peptide treatments are used, then therapeutic effects are achieved, but challenges in crossing the blood-brain barrier limit delivery efficiency
Solution Approach 1:
The patent modifies key physicochemical parameters of the peptides including reducing molecular weight, optimizing hydrophobicity balance, and adjusting charge distribution to enhance blood-brain barrier penetration. These parameter optimizations improve passive diffusion capabilities while maintaining therapeutic activity, resolving the delivery efficiency challenge.
Solution Approach 2:
The patent employs carrier molecules or delivery vehicles as intermediaries to facilitate peptide transport across the blood-brain barrier. These intermediaries protect the peptides from degradation, enhance their solubility, and promote active or facilitated transport mechanisms, thereby improving delivery efficiency without compromising therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compounds effectively reduce calcium influx, acetylcholinesterase activity, and beta-amyloid production, offering improved therapeutic utility for neurodegenerative disorders while potentially enhancing brain penetration, thus providing a more effective and safer treatment option.
Implementation Method 1
Design and synthesis of novel peptides and peptidomimetics with high affinity for the α7 nicotinic-receptor, specifically blocking the toxic effects of endogenous peptides T30 and beta-amyloid production
Implementation Method 2
Acute effects of T14 and T30 are that they:—(i) modulate calcium entry into neurons in brain slices over time scales from milliseconds to hours
Implementation Method 3
The compounds effectively reduce calcium influx, acetylcholinesterase activity, and beta-amyloid production
Data Source
AI summary
The invention relates to neurodegenerative disorders, and in particular to novel peptides, peptidomimetics, compositions, therapies and methods for treating such conditions, for example Alzheimer's disease.